Setting the landscape: are we close? Can the
development be safely accelerated?
Free Virtual Seminar, sign up via the form below.
We are in the middle of a historic pandemic. Researchers around the globe are
working intensely to launch a vaccine targeting the COVID-19 virus. A scientific,
political and commercial race, raising numerous questions. How can a development
process, that usually takes up to 10 years suddenly be shortened to less than 2 years?
This, without compromising safety? Who are the primary target groups? Which
pharmaceutical technologies are currently being exploited to design the COVID-19
vaccine and how close are we actually to launch of a safe and effective vaccine?
- 14.00-14.05 Welcome by Danish Pharmaceutical Society
Stine Harloff-Helleberg, Assistant Professor, Dept. of Pharmacy, UCPH/
Danish Pharmaceutical Society
- 14.05-14.25 Status from the clinic: what is needed from a COVID-19 vaccine?
Thomas Benfield, Professor of Infectious Diseases, Hvidovre Hospital
- 14.30-15.00 Vaccine technologies: how close are we?
Ali Salanti, Professor, Dept. of Immunology and Microbiology, UCPH
- 15.05-15.35 Can the development process be safely accelerated?
Nikolaj Brun, Director of Division Medical Evaluation and Biostatistics,
Danish Medicines Agency
- 15.40-16.00 How should we evaluate potential long-term effects?
Christine Stabell Benn, Clinical Professor, Uni. of Southern Denmark
- 16.05-16.20 Discussion and wrap up
Steen Ingwersen & Lise Sylvest Helledi,
Danish Pharmaceutical Society/ Novo Nordisk
Registration via www.farmaceutisk-selskab.dk.